Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov .
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov .

Dr. Asifa Haider

Dr. Asifa Haider

Scientific Review Officer



Biography

Division:
Division of Translational and Clinical Sciences DTCS
Review Branch:
Cancer Diagnosis, Prevention & Therapeutics CDPT
Study Section:
Cancer Diagnostics and Treatments (CDT) SBIR/STTR SEP CDPT13

Dr. Asifa Haider holds a Ph.D. in molecular pharmacology from New York Medical College, US, and is a licensed pharmacist from ETH-Zurich, Switzerland. She completed a postdoctoral fellowship at Rockefeller University, NY. She applied pharmacogenomics to evaluate the role of immune microenvironments in preclinical and clinical oncology and autoimmune studies. During her career in biotech/pharma, her focus has been to understand immune pathways and molecular mechanisms underlying diseases and developing molecular biomarkers for early detection, risk assessment, diagnosis, and therapeutic development. She supported early- and late-phase clinical trials as principal scientist, scientific/project manager, and translational biomarker leader in small businesses and large pharmaceutical companies, including Novartis, Sanofi, and Cellectis Inc. As a translational scientist, she has more than 15 years of experience in implementing and developing strategies for immune oncology, small molecules, antibodies, autologous and allogeneic Chimeric Antigen Receptor T cells (CAR T), biomarkers, and companion diagnostics.

 

Last updated: 08/22/2025 05:01